MARIDEBART CAFRAGLUTIDE
UNII Z24U3U73HN

Substance Identification & Data

This profile provides standardized clinical and technical data for Maridebart Cafraglutide, uniquely identified by the FDA Unique Ingredient Identifier (UNII) Z24U3U73HN.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2760218-55-9 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

Z24U3U73HN

CAS Registry Number

2760218-55-9

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

MARIDEBART CAFRAGLUTIDE

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C199209

National Cancer Institute reference terminology for clinical and research data.

INN ID

12602

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

NO-219

Identifier assigned by the United States Adopted Names Council.

Substance Type

Maridebart Cafraglutide

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Maridebart Cafraglutide. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Maridebart Cafraglutide

Common Names & Synonyms

Immunoglobulin G1, anti-(glucose-dependent insulinotropic polypeptide receptor) [275-cysteine,295-cysteine,300-glycine,305-cysteine] (human γ1-chain), disulfide with human κ-chain, dimer

Immunoglobulin G1, anti-(glucose-dependent insulinotropic polypeptide receptor) [275-cysteine,295-cysteine,300-glycine,305-cysteine] (human γ1-chain), disulfide with human κ-chain, dimer, 275,275′-bis(thioether) with 7-37-glucagon-like peptide I [8-(2-methylalanine),16-tyrosine,22-glutamic acid,36-glycine] (human) fusion protein with peptide linker ((GGGGS)3-N6-(2-mercaptoacetyl)lysinamide)

Immunoglobulin G1-kappa, anti-[Homo sapiens GIPR (gastric inhibitory polypeptide receptor)], Homo sapiens monoclonal antibody; gamma1 heavy chain Homo sapiens (1-450) [VH (Homo sapiens IGHV3-33*01 (92.9%)-(IGHD) -IGHJ4*01 (100%), CDRIMGT [8.8.13] (26-33.51-58.97-109)) (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14, G1v64 CH2 C36, G1v54-30 CH2 C83, G84.4, C85 (CH1 R120>K (217) (121-218), hinge 1-15 (219-233), CH2 E36>C (275), R83>C (295), N84.4>G (300), V85>C (305) (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain Homo sapiens (1'-214') [VKAPPA (Homo sapiens IGKV3-15*01 (97.9%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27-32.51-53.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

MARIDEBART CAFRAGLUTIDE [USAN]

gamma1 heavy chain Homo sapiens (1-450) [VH (Homo sapiens IGHV3-33*01 (92.9%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.13] (26-33.51-58.97-109)) (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14, G1v64 CH2 C36, G1v54-30 CH2 C83, G84.4, C85 (CH1 R120>K (217) (121-218), hinge 1-15 (219-233), CH2 E36>C (275), R83>C (295), N84.4>G (300), V85>C (305) (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV3-15*01 (97.9%)-IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27-32.51-53.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa; 275,275''-bis(thioether) conjugated to a glucagon-like peptide 1(GLP-1) analogue (GCG (glucagon) 98-126, GLP-1 7-35 A8>methylalanine (2), V16>Y (10), G22>E (16)), via a fused 18-mer linker (diglycyl- tris(tetraglycyl-seryl)-lysinamide

maridebart cafraglutide [INN]